GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » ROE %

Universal Ibogaine (TSXV:IBO) ROE % : -52.13% (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Universal Ibogaine's annualized net income for the quarter that ended in Jan. 2024 was C$-0.89 Mil. Universal Ibogaine's average Total Stockholders Equity over the quarter that ended in Jan. 2024 was C$1.70 Mil. Therefore, Universal Ibogaine's annualized ROE % for the quarter that ended in Jan. 2024 was -52.13%.

The historical rank and industry rank for Universal Ibogaine's ROE % or its related term are showing as below:

TSXV:IBO' s ROE % Range Over the Past 10 Years
Min: -639.56   Med: -100.67   Max: -39.84
Current: -59.32

During the past 7 years, Universal Ibogaine's highest ROE % was -39.84%. The lowest was -639.56%. And the median was -100.67%.

TSXV:IBO's ROE % is ranked worse than
59.78% of 1360 companies
in the Biotechnology industry
Industry Median: -43.445 vs TSXV:IBO: -59.32

Universal Ibogaine ROE % Historical Data

The historical data trend for Universal Ibogaine's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine ROE % Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23
ROE %
Get a 7-Day Free Trial -39.84 -80.82 -639.56 -532.93 -83.93

Universal Ibogaine Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -108.50 -80.53 -54.45 -48.88 -52.13

Competitive Comparison of Universal Ibogaine's ROE %

For the Biotechnology subindustry, Universal Ibogaine's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Ibogaine's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's ROE % distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's ROE % falls into.



Universal Ibogaine ROE % Calculation

Universal Ibogaine's annualized ROE % for the fiscal year that ended in Jul. 2023 is calculated as

ROE %=Net Income (A: Jul. 2023 )/( (Total Stockholders Equity (A: Jul. 2022 )+Total Stockholders Equity (A: Jul. 2023 ))/ count )
=-2.39/( (3.943+1.752)/ 2 )
=-2.39/2.8475
=-83.93 %

Universal Ibogaine's annualized ROE % for the quarter that ended in Jan. 2024 is calculated as

ROE %=Net Income (Q: Jan. 2024 )/( (Total Stockholders Equity (Q: Oct. 2023 )+Total Stockholders Equity (Q: Jan. 2024 ))/ count )
=-0.888/( (1.652+1.755)/ 2 )
=-0.888/1.7035
=-52.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2024) net income data. ROE % is displayed in the 30-year financial page.


Universal Ibogaine  (TSXV:IBO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=-0.888/1.7035
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.888 / 2.356)*(2.356 / 5.5635)*(5.5635 / 1.7035)
=Net Margin %*Asset Turnover*Equity Multiplier
=-37.69 %*0.4235*3.2659
=ROA %*Equity Multiplier
=-15.96 %*3.2659
=-52.13 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=-0.888/1.7035
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.888 / -0.888) * (-0.888 / -0.744) * (-0.744 / 2.356) * (2.356 / 5.5635) * (5.5635 / 1.7035)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.1935 * -31.58 % * 0.4235 * 3.2659
=-52.13 %

Note: The net income data used here is four times the quarterly (Jan. 2024) net income data. The Revenue data used here is four times the quarterly (Jan. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Universal Ibogaine ROE % Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Ibogaine (TSXV:IBO) Business Description

Traded in Other Exchanges
Address
400 3rd Avenue South west, Suite 1470, Calgary, AB, CAN, T2P 4H2
Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

Universal Ibogaine (TSXV:IBO) Headlines

No Headlines